source
- TRex Bio and Retension Pharma announce plans for IPOs, outlining biotech pipeline fundingBiotech companies Retension Pharmaceuticals and TRex Bio have filed with the SEC indicating they intend to go public this year, adding to the current wave of biotech IPOs. TRex Bio said it will us…
- Compass eyes J&J’s Spravato playbook for upcoming psychedelic drug COMP360 launchCompass executives told BioPharma Dive that, if the FDA approves their treatment, they plan to follow the commercial strategy Johnson & Johnson used for its ketamine spray Spravato. When Spravato…